Recently, from a study population of stage III CRC patients enrolled in a phase III adjuvant chemotherapy study, MSI-H was associated with improved SAR, and KRAS mutation and BRAF mutation were associated with poor SAR [12]. Here, KRAS is linked to colorectal carcinoma.